Brii Biosciences Ltd

Overview

• HeadquartersGeorge Town, Cayman Islands²
• Legal formcompany limited by shares²
• LEI5493000GCQ47MM4EKK44²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressPO Box 309, KY1-1104 George Town, Cayman Islands²
• Registered withGeneral Registry, MC-330199²

See how the biggest companies compare on our leaderboards

Corporate structure

Brii Biosciences Ltd sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

Calendar

Drug trials and FDA: recently

1. Aug 5, 2026Phase 2 trial completed Phase 2 trial of BRII-179, BRII-835 (VIR-2218) and others in For Treatment of Chronic Hepatitis B Virus Infection: primary completion Aug 5, 2026, no results posted yet (ClinicalTrials.gov NCT06491563).³
2. Jul 4, 2023Phase 2 trial completed Phase 2 trial of BRII-835 (VIR-2218), BRII-179 (VBI-2601) with IFN-α and others in Hepatitis B, Chronic: primary completion Jul 4, 2023, results posted Jul 23, 2026 (ClinicalTrials.gov NCT04749368).⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Stakes it holds

Brii Biosciences Ltd has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

• AN2 Therapeutics, Inc.SCHEDULE 13G/A Feb 13, 2023 to Feb 14, 2025⁵
• VBI Vaccines Inc/BCSC 13G Jul 20, 2023⁶